|
 The decision leaves the vaccine's state-backed developers open to
potentially costly compensation claims should there be any
unexpected side-effects. It is something many vaccine-makers have
sought to avoid, by asking for full indemnity - complete protection
from liability claims - from nations they sell to.
The approach is different from many places in the world. In the
United States, for example, liability for COVID-19 vaccines has been
shifted fully to the U.S. government. This shields the developers
because widespread inoculation against the disease is considered a
benefit to society.
With the global vaccine race hotting up, and dozens of candidates
being tested on humans, backers of Russia's 'Sputnik-V' shot see
liability as a key battleground as they aim to capture market share.
"Russia is so confident in its vaccine that it has not asked for
full indemnity and this is a major differentiating factor versus any
Western vaccine," said Kirill Dmitriev, head of the Russian Direct
Investment Fund (RDIF), the state sovereign wealth fund that is
backing the vaccine.
"All of them are asking for full indemnity of legal risks."
Dmitriev did not say whether buyers of the Russian vaccine would be
asked to take on partial liability, and did not give details about
indemnity clauses. His representatives said he had nothing more to
add.
However, the health secretary of the Brazilian state of Bahia, which
plans to buy 50 million doses of Russia's vaccine, told Reuters the
legal risks would be carried by Russian entities.
Vaccine developers around the world are compressing years of
development into months, raising the possibility of unexpected
consequences and making the issue of compensation claims a key point
in supply deal negotiations.
For example, British drugmaker AstraZeneca <AZN.L>, which has
developed a vaccine with Oxford University, has been granted full
protection from any future liability claims by many countries with
which it has signed supply deals, a senior executive told Reuters in
July.
Dmitriev's comments came after some scientists expressed concerns
about the safety and efficacy of Sputnik-V, which the Russian
government approved for use before completing large-scale human
trials.
BRAZILIAN BUYERS
Sputnik-V was developed by Moscow's Gamaleya Institute, a state
research body. The RDIF, which is marketing the vaccine abroad, will
shoulder some of the legal risks in supply contracts along with
pharmaceutical firms in the fund's portfolio which are producing the
shot.
"We are confident in the long-term consequences," Dmitriev said. "We
are putting our money where our mouth is by not asking for full
indemnity in partnerships we create in different countries."
[to top of second column] |
Thus far, RDIF has announced deals to supply just over 200 million doses, half
to Latin America and half to India. The fund says it has orders for as much as 1
billion doses.
Fábio Vilas-Boas, health secretary of Brazil's Bahia state, which is placing the
50-million-dose order, told Reuters the legal risks would be carried by the
Russian pharmaceutical firms producing and supplying the vaccine.
"In the case of any adverse event, nothing will stop people who feel they have
been harmed from filing a class action against any of the pharmaceutical
companies," said Fábio Vilas-Boas, who negotiated the testing and letter of
intent with RDIF.
Neither Bahia nor Paraná, a Brazilian state which plans to conduct trials of
Sputnik-V on 10,000 volunteers, have actually signed contracts for supply of the
vaccine, according to Bahia's Vilas-Boas and the Paraná state governor's chief
of staff, Guto Silva, who also negotiated with the Russian side.
Thus far, deals have been formalised only in memorandums of understanding, as
contracts are awaiting the vaccine's approval by Brazil's health regulators.
INSURANCE FOR VOLUNTEERS
Russia has staked its scientific reputation on the results after approving the
vaccine for domestic use before mass testing had even begun, becoming the first
country to licence a COVID-19 vaccine.
Late-stage trials, known as Phase III, are currently ongoing in Russia, with at
least 40,000 volunteers taking part. Initial results are expected in October or
November.
Volunteers in its Phase III trial are unpaid, but their insurance is covered,
including a payout of 2 million roubles ($26,430) in case of death, one
volunteer told Reuters.
RDIF also expects to run trials of the vaccine abroad, with plans already in
place with Indian pharmaceutical firm Dr Reddy's and with Brazil's Paraná state,
both pending regulatory approval.
Many people involved in the Sputnik-V's development, including Dmitriev, have
tried the jab on themselves in a bid to convince the world of the safety of a
Russian-made vaccine.
Dmitriev said he was not concerned about the risk of compensation claims against
RDIF.
"We know it will not happen. Because the vaccine has been studied for decades,"
he said.
"We know we will not have ... billions and billions of liabilities because we
have a proven platform and they don't," he said. "Simple."
(Reporting by Polina Ivanova in Moscow and Anthony Boadle in Brasilia; Writing
by Polina Ivanova; Editing by Pravin Char)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
